IgG1 pan-neurofascin antibodies identify a severe yet treatable neuropathy with a high mortality
Janev Fehmi, Alexander J. Davies, R. Jon Walters, Tim Lavin, Ryan Keh, Alexander M. Rossor, Tudor Munteanu, Norman Delanty, Rhys Roberts, Dirk B□umer, Graham Lennox, View ORCID ProfileSimon Rinaldi
doi: https://doi.org/10.1101/2021.01.29.21250485
Janev Fehmi
1Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, UK
MBBSAlexander J. Davies
1Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, UK
PhDR. Jon Walters
2Department of Neurology, Morriston Hospital, Morriston, Swansea, Wales SA6 6NL, UK
MDTim Lavin
3Manchester Centre for Clinical Neuroscience, Salford Royal NHS Foundation Trust, UK
MBBSRyan Keh
3Manchester Centre for Clinical Neuroscience, Salford Royal NHS Foundation Trust, UK
MBBCHIRAlexander M. Rossor
4MRC Centre for Neuromuscular Disease, National Hospital of Neurology and Neurosurgery and Department of Neuromuscular Diseases, UCL Institute of Neurology, Queen Square, London, UK
FRCP, PhDTudor Munteanu
5Beaumont Hospital, Dublin, Ireland
MDNorman Delanty
5Beaumont Hospital, Dublin, Ireland
MBRhys Roberts
6Department of Clinical Neurosciences, Cambridge Institute for Medical Research, UK
PhDDirk B□umer
6Department of Clinical Neurosciences, Cambridge Institute for Medical Research, UK
DPhilGraham Lennox
7Department of Neurology, Great Western Hospital, Swindon, UK
BM, BChSimon Rinaldi
1Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, UK
PhD
Data Availability
The data that support the findings of this study are available from the corresponding author, upon reasonable request.
Posted February 01, 2021.
IgG1 pan-neurofascin antibodies identify a severe yet treatable neuropathy with a high mortality
Janev Fehmi, Alexander J. Davies, R. Jon Walters, Tim Lavin, Ryan Keh, Alexander M. Rossor, Tudor Munteanu, Norman Delanty, Rhys Roberts, Dirk B□umer, Graham Lennox, Simon Rinaldi
medRxiv 2021.01.29.21250485; doi: https://doi.org/10.1101/2021.01.29.21250485
IgG1 pan-neurofascin antibodies identify a severe yet treatable neuropathy with a high mortality
Janev Fehmi, Alexander J. Davies, R. Jon Walters, Tim Lavin, Ryan Keh, Alexander M. Rossor, Tudor Munteanu, Norman Delanty, Rhys Roberts, Dirk B□umer, Graham Lennox, Simon Rinaldi
medRxiv 2021.01.29.21250485; doi: https://doi.org/10.1101/2021.01.29.21250485
Subject Area
Subject Areas
- Addiction Medicine (349)
- Allergy and Immunology (668)
- Allergy and Immunology (668)
- Anesthesia (181)
- Cardiovascular Medicine (2648)
- Dermatology (223)
- Emergency Medicine (399)
- Epidemiology (12228)
- Forensic Medicine (10)
- Gastroenterology (759)
- Genetic and Genomic Medicine (4103)
- Geriatric Medicine (387)
- Health Economics (680)
- Health Informatics (2657)
- Health Policy (1005)
- Hematology (363)
- HIV/AIDS (851)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (436)
- Neurology (3882)
- Nursing (209)
- Nutrition (577)
- Oncology (2030)
- Ophthalmology (585)
- Orthopedics (240)
- Otolaryngology (306)
- Pain Medicine (250)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1115)
- Primary Care Research (452)
- Public and Global Health (6527)
- Radiology and Imaging (1403)
- Respiratory Medicine (871)
- Rheumatology (409)
- Sports Medicine (342)
- Surgery (448)
- Toxicology (53)
- Transplantation (185)
- Urology (165)